CME Group Inc. (CME) Upgraded to Buy at UBS Despite 2011 Underperformance

CME Group Inc. has been upgraded today by the securities research analysts at investment firm UBS which increased CME Group from a “neutral” rating to “buy.”  UBS noted with their buy rating that CME Group’s diversified product portfolio could benefit via continued recovery of the economy and therefore, higher interest rates in the following year, 2012.  UBS did not adjust their price target for ‘CME’ and remains fixed at $318 dollars.  CME is currently trending north during the intraday trading session for a second day in a row. CME had previously been on a downtrend for four days prior to recent gains.

CME Group is slated to release their next earnings report on July 28th, 2011  and the current consensus EPS estimate is expected to be $4.16.  CME’s last earnings report was released on April 28th, 2011, and announced EPS of $4.36 with revenue totaling $832 million which was up 20.1 % year to year.  CME is currently trading below its 50 & 200-day moving averages and 2011 is currently a down year for the company.

CME Group Inc. offers a wide range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, metals, weather and real estate.  The company has market capitalization of $17,987,235,230 and 67,049,0000 shares outstanding.  CME has a 52-week high of $328 with the low being $234.50 dollars.

Latest News

Somewhat Positive Media Coverage Somewhat Unlikely to Impact Gemphire Therapeutics  Stock Price
Somewhat Positive Media Coverage Somewhat Unlikely to Impact Gemphire Therapeutics Stock Price
Aviat Networks  Given Daily Media Impact Rating of 0.09
Aviat Networks Given Daily Media Impact Rating of 0.09
Papa Murphy’s  Getting Somewhat Positive News Coverage, Report Shows
Papa Murphy’s Getting Somewhat Positive News Coverage, Report Shows
EXFO  Given Average Recommendation of “Hold” by Brokerages
EXFO Given Average Recommendation of “Hold” by Brokerages
Brokerages Set ANI Pharmaceuticals Inc Common Stock  Price Target at $79.00
Brokerages Set ANI Pharmaceuticals Inc Common Stock Price Target at $79.00
MediBloc [QRC20] Price Tops $0.0061 on Top Exchanges
MediBloc [QRC20] Price Tops $0.0061 on Top Exchanges


© 2006-2018 Ticker Report. Google+.